VRAX

Virax Biolabs (VRAX)

Virax Biolabs Group Ltd

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VRAX

1 2 3 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/04/25	21 : 00	PR Newswire (US)	Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024	NASDAQ:VRAX	Virax Biolabs Group Ltd
2024/04/16	20 : 30	PR Newswire (US)	Virax Biolabs to Participate at ESCMID Global 2024	NASDAQ:VRAX	Virax Biolabs Group Ltd
2024/03/16	05 : 30	PR Newswire (US)	Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency	NASDAQ:VRAX	Virax Biolabs Group Ltd
2024/01/23	07 : 28	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2024/01/23	07 : 27	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2024/01/12	21 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	21 : 34	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	21 : 30	PR Newswire (US)	Virax Biolabs Forges Strategic Research Collaboration with University of Manchester and the Northern Care Alliance Foundation Trust to Enhance Understanding of Immune Responses in COVID Patients	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	06 : 12	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	06 : 12	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	06 : 06	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/21	06 : 03	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/18	21 : 37	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/18	21 : 30	PR Newswire (US)	Virax Biolabs' CEO James Foster Issues Letter to Shareholders	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/18	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/14	21 : 43	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/14	21 : 30	PR Newswire (US)	Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/08	20 : 03	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/12/06	06 : 06	Edgar (US Regulatory)	Form F-3 - Registration statement by foreign private issuers	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/11/09	06 : 11	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/11/01	05 : 38	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/10/18	05 : 05	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/10/12	21 : 00	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/10/04	20 : 24	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/09/12	20 : 49	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/09/12	20 : 30	PR Newswire (US)	Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/09/01	20 : 37	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/09/01	20 : 30	PR Newswire (US)	Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/08/03	21 : 39	Edgar (US Regulatory)	Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]	NASDAQ:VRAX	Virax Biolabs Group Ltd
2023/08/03	20 : 30	PR Newswire (US)	Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid	NASDAQ:VRAX	Virax Biolabs Group Ltd